Early Access Program of Lazertinib in Republic of Korea

NCT04829422 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Lazertinib 240 mg

Sponsor

Yuhan Corporation